Special Issue

Metal Anticancer Complexes

Message from the Guest Editor

Despite breakthrough therapies for the treatment of cancer based on platinum, arsenic, and ruthenium compounds, metal complexes have received relatively little attention from the pharmaceutical industry and the chemical biology/medicinal chemistry research community as a whole. A number of small spinout companies have now started in-house research programs aimed at addressing key bioinorganic aspects of medicine; however, few large pharmaceutical companies have such mechanisms in place. The versatility of metal complexes, which arises from the choice of metal, oxidation state, redox activity, number and type of ligands, coordination geometry, and magnetic and optical properties, deserves to be investigated further in the context of rational drug design. This Special Issue of *Molecules* aims to showcase recent advancements in any aspect of metal-based anticancer therapeutics design and development. Synthetic, biophysical, in vitro, and in vivo studies are all welcome. Review articles that describe the current state of metal-based cancer therapeutics development, in any context, are also welcome.

Guest Editor

Dr. Kogularamanan Suntharalingam
School of Chemistry, University of Leicester, University Road, Leicester LE1 7RH, UK

Deadline for manuscript submissions

closed (31 October 2020)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.4
Indexed in PubMed

mdpi.com/si/24607

Molecules
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.4
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2024).